Doses - EPOETIN ALFA, EPOETIN BETA, ERYTHROPOIETIN, EPO, r-HUEPO
Dogs: 
As adjunctive therapy for the treatment of anemia associated with end-stage renal disease: a) Initially, 100 Units/kg SubQ 3 times weekly, this dose is maintained for the first 12weeks of therapy or until the target hematocrit of 37-45% is attained. Once the lowerrange of the target hematocrit is attained, the dosing interval is changed to twice weekly(or once weekly if polycythemia needs to be prevented.) If anemia recurs with twiceweekly injections, three times weekly injections are reinstituted. If adequate control isnot achieved with these dosing intervals, then dose may be increased by an additional 25- 50 Units/kg. Maintenance doses usually fall in the 75 - 100 mg/kg twice to three timesweekly range. Do not adjust dosage more often than once every three weeks (due to thelong lag time for a response). If an adequate response is not achieved, reevaluate for irondeficiency, other blood loss, hemolysis, or infectious, neoplastic or inflammatory diseaseprocesses that could retard erythropoiesis. (Cowgill 1992)
Cats: 
As adjunctive therapy for the treatment of anemia associated with end-stage renal disease: a) As above, but the target hematocrit is: 30 - 40%. (Cowgill 1992)
Monitoring Parameters - 1) Hematocrit; PCV; (Initially weekly, then when dose and HCt isstable, at 1-2 month intervals); 2) Blood Pressure (initially, at least monthly then every 1-2 monthsthereafter); 3) Renal Function Status; 4) Iron status (serum iron, TIBC), RBC indices (initially andregularly during therapy to insure adequate iron availability)
Client Information - Clients should be made aware of the "investigational nature" of this agentand should understand the potential risks as well as the benefits of therapy. For outpatient administration, training in proper injection techniques, drug handling and storage considerations shouldbe performed.
Dosage Forms/Preparations/FDA Approval Status/Withholding Times - Veterinary-Approved Products: None